Cargando…

New Insights in Thrombin Inhibition Structure–Activity Relationships by Characterization of Octadecasaccharides from Low Molecular Weight Heparin †

Low Molecular Weight Heparins (LMWH) are complex anticoagulant drugs that mainly inhibit the blood coagulation cascade through indirect interaction with antithrombin. While inhibition of the factor Xa is well described, little is known about the polysaccharide structure inhibiting thrombin. In fact,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mourier, Pierre A. J., Guichard, Olivier Y., Herman, Fréderic, Sizun, Philippe, Viskov, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6155232/ https://www.ncbi.nlm.nih.gov/pubmed/28282887 http://dx.doi.org/10.3390/molecules22030428

Ejemplares similares

Oligosaccharide Chromatographic Techniques for Quantitation of Structural Process-Related Impurities in Heparin Resulting From 2-O Desulfation
por: Anger, Pascal, et al.
Publicado: (2018)

Using heparan sulfate octadecasaccharide (18-mer) as a multi-target agent to protect against sepsis
por: Liao, Yi-En, et al.
Publicado: (2023)

Thrombin Decrease in Thrombin Generation after Heparin Administration in a Homozygous Type II Heparin-Binding Site Antithrombin-Deficient Pregnant Woman
por: Malíková, Ivana, et al.
Publicado: (2023)

Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial
por: Arantes, Flávia B. B., et al.
Publicado: (2019)

Unfractionated and low molecular weight heparin
por: Lima, Marcelo, et al.
Publicado: (2014)

Validation of high concentrated thrombin time assay for unfractionated heparin monitoring
por: Apipongrat, Dollapak, et al.
Publicado: (2022)

Heparin/low molecular weight heparins: Thrombocytopenia: 7 case reports
Publicado: (2021)

Monitoring Low Molecular Weight Heparins at Therapeutic Levels: Dose-Responses of, and Correlations and Differences between aPTT, Anti-Factor Xa and Thrombin Generation Assays
por: Thomas, Owain, et al.
Publicado: (2015)

Effect of heparin and low-molecular weight heparin on serum potassium and sodium levels
por: Bengalorkar, Girish M., et al.
Publicado: (2011)

Comparison of Low-Molecular-Weight Heparins Prepared From Ovine Heparins With Enoxaparin
por: Chen, Jianle, et al.
Publicado: (2019)

Building Block Analysis of ATIII Affinity Fractions of Heparins: Application to the ATIII Binding Capacity of Non-conventional 3-O-Sulfated Sequences
por: Mourier, Pierre
Publicado: (2022)

Comparative Anticoagulant and Thrombin Generation Inhibitory Profile of Heparin, Sulodexide and Its Components
por: Siddiqui, Fakiha, et al.
Publicado: (2020)

Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: a systematic review and meta-analysis
por: Lazrak, Hind Harrak, et al.
Publicado: (2017)

Arterial indications for the low molecular weight heparins
por: Ageno, Walter, et al.
Publicado: (2001)

A meta-analysis of bridging anticoagulation between low molecular weight heparin and heparin
por: Tao, Ende, et al.
Publicado: (2020)

Structural Characterization of the Low-Molecular-Weight Heparin Dalteparin by Combining Different Analytical Strategies
por: Bisio, Antonella, et al.
Publicado: (2017)

Commercial Low Molecular Weight Heparins — Patent Ecosystem and Technology Paradigm for Quality Characterization
por: Iqbal, Zarina, et al.
Publicado: (2022)

Heparinase Digestion of 3-O-Sulfated Sequences: Selective Heparinase II Digestion for Separation and Identification of Binding Sequences Present in ATIII Affinity Fractions of Bovine Intestinal Heparins
por: Mourier, Pierre
Publicado: (2022)

Effect of a Direct Thrombin Inhibitor Compared with Dalteparin and Unfractionated Heparin on Human Osteoblasts
por: Winkler, Tobias, et al.
Publicado: (2011)

Rates of clinically apparent heparin-induced thrombocytopenia for unfractionated heparin vs. low molecular weight heparin in non-surgical patients are low and similar
por: Locke, Charles FS, et al.
Publicado: (2005)

Low-molecular-weight heparins in the treatment of venous thromboembolism
por: Ageno , Walter, et al.
Publicado: (2000)

The Effect of Low Molecular Weight Heparins on Fracture Healing
por: Kapetanakis, Stylianos, et al.
Publicado: (2015)

Low-molecular weight heparin infusion as anticoagulation for haemodialysis
por: Wong, Steve Siu-Man, et al.
Publicado: (2016)

COVID-19, Low-Molecular-Weight Heparin, and Hemodialysis
por: Perna, Alessandra F., et al.
Publicado: (2020)

Management of intentional overdose of low-molecular-weight heparin
por: Lu, Clara, et al.
Publicado: (2022)

Specific Non-Reducing Ends in Heparins from Different Animal Origins: Building Blocks Analysis Using Reductive Amination Tagging by Sulfanilic Acid
por: Mourier, Pierre A. J.
Publicado: (2020)

Low-Molecular-Weight Heparin and Unfractionated Heparin Decrease Th-1, 2, and 17 Expressions
por: Huang, Jing-Ning, et al.
Publicado: (2014)

Is the Incidence Trend of Heparin-Induced Thrombocytopenia Decreased by the Increased Use of Low-Molecular-Weight-Heparin?
por: Al-Eidan, Fahad A S
Publicado: (2015)

Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients
por: Volteas, Panagiotis, et al.
Publicado: (2022)

Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease
por: Shute, Janis Kay
Publicado: (2023)

Characterization of the interaction between platelet factor 4 and homogeneous synthetic low molecular weight heparins
por: Nguyen, Thi-Huong, et al.
Publicado: (2019)

Recombinant dermatan sulfate is a potent activator of heparin cofactor II-dependent inhibition of thrombin
por: Tykesson, Emil, et al.
Publicado: (2019)

The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis
por: Afshari, Daryoush, et al.
Publicado: (2015)

Why differentiate low molecular weight heparins for venous thromboembolism?
por: Fareed, Jawed, et al.
Publicado: (2007)

Update on the clinical use of the low-molecular-weight heparin, parnaparin
por: Camporese, Giuseppe, et al.
Publicado: (2009)

The potential benefits of low-molecular-weight heparins in cancer patients
por: Robert, Francisco
Publicado: (2010)

Diffuse alveolar hemorrhage associated with low molecular weight heparin
por: Hayashi, Shinichi, et al.
Publicado: (2013)

Low molecular weight heparin use in unexplained recurrent miscarriage
por: Yuksel, Halide, et al.
Publicado: (2014)

Use of low-molecular-weight heparin in COVID-19 patients
por: Kow, Chia Siang, et al.
Publicado: (2020)

Low molecular weight heparin in COVID-19: benefits and concerns
por: Makarem, Adham, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ifv0qe040e0hemqeu6h3fjj8lq